JP2010535252A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535252A5
JP2010535252A5 JP2010520219A JP2010520219A JP2010535252A5 JP 2010535252 A5 JP2010535252 A5 JP 2010535252A5 JP 2010520219 A JP2010520219 A JP 2010520219A JP 2010520219 A JP2010520219 A JP 2010520219A JP 2010535252 A5 JP2010535252 A5 JP 2010535252A5
Authority
JP
Japan
Prior art keywords
compound
diabetes
type
metabolic
nachr agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010520219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535252A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/071893 external-priority patent/WO2009018511A2/en
Publication of JP2010535252A publication Critical patent/JP2010535252A/ja
Publication of JP2010535252A5 publication Critical patent/JP2010535252A5/ja
Pending legal-status Critical Current

Links

JP2010520219A 2007-08-02 2008-08-01 代謝障害を治療または予防するためのα7nAChRアゴニスト Pending JP2010535252A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95361307P 2007-08-02 2007-08-02
US95361407P 2007-08-02 2007-08-02
US95361007P 2007-08-02 2007-08-02
US97165407P 2007-09-12 2007-09-12
PCT/US2008/071893 WO2009018511A2 (en) 2007-08-02 2008-08-01 Alpha7 nachr agonists for treating or preventing metabolic disorders

Publications (2)

Publication Number Publication Date
JP2010535252A JP2010535252A (ja) 2010-11-18
JP2010535252A5 true JP2010535252A5 (OSRAM) 2011-01-06

Family

ID=39945177

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010520219A Pending JP2010535252A (ja) 2007-08-02 2008-08-01 代謝障害を治療または予防するためのα7nAChRアゴニスト
JP2010520213A Active JP5358573B2 (ja) 2007-08-02 2008-08-01 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148087A Active JP5852611B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148091A Active JP6106549B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010520213A Active JP5358573B2 (ja) 2007-08-02 2008-08-01 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148087A Active JP5852611B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法
JP2013148091A Active JP6106549B2 (ja) 2007-08-02 2013-07-17 (2s,3r)−n−(2−((3−ピリジニル)メチル)−1−アザビシクロ[2.2.2]オクタ−3−イル)ベンゾフラン−2−カルボキサミド、その新規塩形態およびその使用方法

Country Status (35)

Country Link
US (6) US20110124678A1 (OSRAM)
EP (6) EP2465501B1 (OSRAM)
JP (4) JP2010535252A (OSRAM)
KR (2) KR20100051684A (OSRAM)
CN (4) CN101868237A (OSRAM)
AR (1) AR067775A1 (OSRAM)
AU (3) AU2008283813A1 (OSRAM)
BR (2) BRPI0814889A2 (OSRAM)
CA (2) CA2694510A1 (OSRAM)
CL (3) CL2008002271A1 (OSRAM)
CO (2) CO6260080A2 (OSRAM)
CY (1) CY1113561T1 (OSRAM)
DK (2) DK2182949T3 (OSRAM)
EC (2) ECSP10010008A (OSRAM)
ES (3) ES2606752T3 (OSRAM)
HR (1) HRP20130286T1 (OSRAM)
HU (1) HUE030387T2 (OSRAM)
IL (1) IL218976A0 (OSRAM)
ME (1) ME01508B (OSRAM)
MX (3) MX2010001293A (OSRAM)
MY (1) MY148002A (OSRAM)
NO (2) NO20100077L (OSRAM)
NZ (2) NZ582828A (OSRAM)
PE (3) PE20121820A1 (OSRAM)
PH (2) PH12012501513A1 (OSRAM)
PL (1) PL2182949T3 (OSRAM)
PT (1) PT2182949E (OSRAM)
RS (1) RS52743B (OSRAM)
RU (2) RU2012140148A (OSRAM)
SA (2) SA08290475B1 (OSRAM)
SI (1) SI2182949T1 (OSRAM)
TW (3) TW201402116A (OSRAM)
UY (1) UY31265A (OSRAM)
WO (2) WO2009018505A1 (OSRAM)
ZA (1) ZA201000719B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
US20130225560A1 (en) * 2010-07-26 2013-08-29 Envivo Pharmaceuticals, Inc. Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors
CN106074548A (zh) 2010-09-23 2016-11-09 艾伯维巴哈马有限公司 氮杂金刚烷衍生物的一水合物
JP2014502996A (ja) * 2011-01-18 2014-02-06 ターガセプト,インコーポレイテッド 統合失調症における認知障害の治療
MX2013008704A (es) 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
PL2685979T3 (pl) 2011-03-18 2017-02-28 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
EP2727604A4 (en) 2011-06-30 2015-03-18 Toray Industries ANTIPRURIGINOUS AGENT
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之1,4-二氮雜雙環[3.2.2]壬烷
CA3083244C (en) 2011-10-20 2023-01-03 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
US9993556B2 (en) * 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
JP6114951B2 (ja) 2012-12-11 2017-04-19 ノバルティス アーゲー アルファ7ニコチン性アセチルコリン受容体アクチベーターによる処置に対する応答性を予測するバイオマーカー
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
ES2883232T3 (es) 2013-01-15 2021-12-07 Novartis Ag Uso de agonistas del receptor nicotínico de acetilcolina alfa 7
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN104288771B (zh) * 2014-09-30 2017-03-15 郑州大学第五附属医院 α7nAChR激动剂的新用途
US10857140B2 (en) 2015-05-06 2020-12-08 The Regents Of The University Of California K-Ras modulators
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10282666B1 (en) 2015-11-10 2019-05-07 Google Llc Coherency detection and information management system
RU2675111C2 (ru) * 2017-03-31 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ стимуляции нейрогенеза в гиппокампе
EP3612526A2 (en) 2017-04-20 2020-02-26 The Regents of the University of California K-ras modulators
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203990A (en) 1979-04-30 1980-05-20 G. D. Searle & Co. Anti-diarrheal 2-substituted quinuclidines
DE58906678D1 (de) 1988-07-28 1994-02-24 Ciba Geigy Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung.
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0402056A3 (en) 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
CA2022886A1 (en) 1989-08-08 1991-02-09 Raymond Baker Substituted pyridines, their preparation, formulations and use in dementia
IN173570B (OSRAM) 1989-11-23 1994-06-04 Pfizer
DK40890D0 (da) 1990-02-16 1990-02-16 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0492903A1 (en) 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
EP0573568B1 (en) 1991-03-01 2001-01-24 University Of Florida Research Foundation, Inc. Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
DE69332641T2 (de) 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IL109451A0 (en) * 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
WO1995003306A1 (en) 1993-07-22 1995-02-02 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5510355A (en) 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5824692A (en) 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5859004A (en) 1995-02-17 1999-01-12 Novo Nordisk A/S Use of heterocyclic compounds for the treatment of conditions caused by malfunctioning of the nicotinic cholinergic system
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JPH11508540A (ja) 1995-06-29 1999-07-27 ノボ ノルディスク アクティーゼルスカブ 新規の置換アザ環式またはアザ二環式化合物
AU7083596A (en) 1995-09-22 1997-04-09 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
HUP0002713A3 (en) 1997-05-30 2001-02-28 Neurosearch As 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
DE69907894T2 (de) 1998-04-02 2004-03-11 Targacept, Inc. Azatricyclo[3.3.1.1]decanderivate und diese enthaltende phrmazeutische zubereitungen
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6734215B2 (en) 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
SE9904176D0 (sv) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
EA005520B1 (ru) 2000-06-27 2005-04-28 Лабораториос С.А.Л.В.А.Т.,С.А. Карбаматы, полученные из арилалкиламинов
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
KR100869722B1 (ko) 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 m3 길항제로서 그의사용
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
EP1397366B1 (en) 2001-06-01 2007-02-07 AstraZeneca AB Novel ligand for nicotinic acetylcholine receptors useful in therapy
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
BR0212123A (pt) 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
WO2003022856A1 (en) 2001-09-12 2003-03-20 Pharmacia & Upjohn Company Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−n−架橋−複素環式芳香族カルボキサミド
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
ES2348282T3 (es) * 2002-04-18 2010-12-02 Astrazeneca Ab Compuestos de tienilo.
BR0309345A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa
MXPA04010191A (es) 2002-04-18 2005-02-03 Astrazeneca Ab Compuestos de furilo.
JP2005537297A (ja) 2002-08-01 2005-12-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルファ−7nachr活性を有する1h−ピラゾールおよび1h−ピロール−アザビシクロ化合物
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
PL375533A1 (en) 2002-08-14 2005-11-28 Neurosearch A/S Novel quinuclidine derivatives and their use
EP2305664A1 (en) 2002-08-30 2011-04-06 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegeneratives diseases
CA2499128C (en) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
CA2503786A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases
JP4750421B2 (ja) 2002-12-06 2011-08-17 ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト α7受容体結合コリン作動性アゴニストを用いる炎症の阻害
JP2006510662A (ja) 2002-12-11 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α7ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療
EP1572300A1 (en) 2002-12-11 2005-09-14 Pharmacia & Upjohn Company LLC Combination for the treatment of adhd
US6917746B2 (en) 2002-12-17 2005-07-12 3M Innovative Properties Company Apparatus and method for creating a fiber optic circuit
US6777617B2 (en) 2002-12-30 2004-08-17 3M Innovative Properties Company Telecommunications terminal
ATE445618T1 (de) 2003-02-27 2009-10-15 Neurosearch As Neue diazabicyclische arylderivate
AU2004255920B2 (en) 2003-07-08 2008-05-15 Astrazeneca Ab Spiro [1-azabicyclo [2.2.2] octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
BRPI0414633A (pt) 2003-09-25 2006-11-07 Astrazeneca Ab composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit
EP1678183A1 (en) 2003-10-21 2006-07-12 AstraZeneca AB Spirofuropyridine aryl derivatives
US20050137217A1 (en) 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
CA2555311A1 (en) * 2004-02-04 2005-08-18 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
CA2567977A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
KR20070015607A (ko) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1h-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
MX2007004269A (es) * 2004-10-20 2007-06-15 Neurosearch As Derivados de arilo diazabiciclico nuevos y su uso medico.
EP1831231A1 (en) 2004-12-15 2007-09-12 AstraZeneca AB Nicotinic acetylcholine receptor ligands
WO2006069097A2 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
CA2610795C (en) 2005-06-07 2015-01-06 University Of Florida Research Foundation, Inc. 3-arylidene-anabaseine compounds as alpha 7 nicotitnic receptor selective ligands
WO2007024814A1 (en) * 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
WO2007038367A1 (en) 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2633868A1 (en) * 2008-02-13 2013-09-04 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics

Similar Documents

Publication Publication Date Title
JP2010535252A5 (OSRAM)
CN101534809B (zh) 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途
JP2008007519A5 (OSRAM)
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
JP2007504174A5 (OSRAM)
JP2009542702A5 (OSRAM)
MX356032B (es) Compuestos indola y métodos para tratar el dolor visceral.
JP2009542699A5 (OSRAM)
JP2013525444A5 (OSRAM)
NZ593754A (en) Dpp-iv inhibitors for treatment of diabetes in paediatric patients
JP2011516417A5 (OSRAM)
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
JP2016185995A5 (OSRAM)
CN1440283A (zh) 有机化合物的联合形式
RU2010143864A (ru) Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
EP2283843A3 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2006503850A5 (OSRAM)
JP2008535785A5 (OSRAM)
WO2007105113A3 (en) Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
US20140045801A1 (en) Pramipexole transdermal delivery for severe headaches
JP2013536837A5 (OSRAM)
WO2007145863A3 (en) Sustained release formulation of naltrexone
RS51388B2 (sr) Primena jedne kombinacije morfina i najmanje jednog opijat antagonista za tretman zavisnosti od opijata i za smanjenje neoralne zloupotrebe kod zavisnika od opijata